Clinical Study Results Sanofi Pharma, including Sanofi Genzyme

Information about sponsored clinical trials and result information are provided for informational purposes only and are not intended to promote any product or use. Clinical study results are intended to report the results of the study that were known at the time of the study's completion. The results therefore do not provide a comprehensive and current review of the safety and efficacy of any drug based upon all information available. Physicians and patients should refer to the current approved product labeling for information on approved indications in their country.
This information is not intended to replace the advice of a health care professional. Only a physician can determine if a specific medicine is the correct or best treatment option for a particular patient. If you have questions, please consult a health care professional.

A - B - C - D - E - F - G - H - I - J - K - L - M - N - O - P - Q - R - S - T - U - V - W - X - Y - Z

Clinical study results Sanofi pharma, including Sanofi Genzyme – Letter S

GENERIC NAME	TRADE NAME	CONDITION	STUDY CODE	STUDY NAME	ACCESS TO STUDY / PROTOCOL	ACCESS TO RESULTS
SARILUMAB	Kevzara	Giant Cell Arteritis	EFC15068	NA	NCT03600805	Tabulated Results
SARILUMAB	Kevzara	Polymyalgia Rheumatica	EFC15160	NA	NCT03600818	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	ACT13480	SARILNIUSATURN	EudraCT: 2012-004845-34	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	EFC13752	SARIL-RA-ONE	EudraCT: 2013-002790-22	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	EFC14092	SARIL-RA-MONARCH	NCT02332590	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	LTS11210	SARIL-RA-EXTEND	NCT01146652	Tabulated Results
SARILUMAB	Kevzara	COVID-19	EFC16844	NA	NCT04327388	Tabulated Results
SARILUMAB	Not marketed	Ankylosing Spondylitis	DRI11073	ALIGN	EudraCT: 2009-016068-35	Summary Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	EFC10832	SARIL-RA-TARGET	EudraCT: 2011-003538-16	Tabulated Results
SARILUMAB	Not marketed	Ankylosing Spondylitis	LTS11298	SUSTAIN	EudraCT: 2010-019263-11	Summary Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	LTS13618	SARIL-RA-HARUKA	NCT02373202	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	EFC11072	RA-MOBILITY	EudraCT: 2009-016266-90	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	EFC14059	SARIL-RA-KAKEHASI	NCT02293902	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	MSC12665	SARIL-RA-EASY	EudraCT: 2012-004339-21	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	SFY13370	SARIL-RA-ASCERTAIN	EudraCT: 2012-003536-23	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	EFC11574	RA-COMPARE	EudraCT: 2012-001984-66	Tabulated Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	ACT11575	NA	EudraCT: 2010-021020-94	Summary Results
SARILUMAB	Kevzara	Rheumatoid Arthritis	SARILL08755	SariPRO	NCT03449758	Tabulated Results
SEMULOPARIN	Not Marketed	Venous Thromboembolism	DRI6243	TREK	NCT00331838	Publication's reference
SEMULOPARIN	Not Marketed	Venous Thromboembolism	EFC10342	SAVE-HIP1	NCT00697099	Publication's reference
SEMULOPARIN	Not Marketed	Venous Thromboembolism	EFC10343	SAVE-HIP2	NCT00721760	Publication's reference
SEMULOPARIN	Not Marketed	Venous Thromboembolism	EFC10571	SAVE-KNEE	NCT00718224	Publication's reference
SEMULOPARIN	Not Marketed	Venous Thromboembolism	EFC10572	SAVE-VEMED	EudraCT: 2008-000228-13	Summary Results
SEMULOPARIN	Not Marketed	Venous Thromboembolism	EFC10636	SAVE-HIP3	NCT00709904	Publication's reference
SEMULOPARIN	Not Marketed	Venous Thromboembolism	EFC6520	SAVE-ABDO	EudraCT: 2007-007942-36	Summary Results
SEMULOPARIN	Not Marketed	Venous Thromboembolism	EFC6521	SAVE-ONCO	NCT00694382	Publication's reference
SEMULOPARIN	Not Marketed	Venous Thromboembolism	PKM11204	NA	NCT01567904	Summary
SENNA + CASSIA	Naturetti (Cassia Fistula + Senna Alexandrina Miller)	Constipation	SENCA_L_04392	NA	NCT00931853	Summary
SENNA + CASSIA	Naturetti (Cassia Fistula + Senna Alexandrina Miller)	Constipation	SENCA_L_04746	NA	NCT00994851	Summary
SEVELAMER CARBONATE	Renvela	Chronic Kidney Disease	DRI12793	NA	NCT01574326	Tabulated Results
SEVELAMER CARBONATE	Renvela	Chronic Kidney Disease	GD3-163-201*	NA	NCT00440648	Summary
SEVELAMER CARBONATE	Renvela	Chronic Kidney Disease	GD3-199-301*	NA	NCT00268957	Summary
SEVELAMER CARBONATE	Renvela	Chronic Kidney Disease	SVCARB00105	NA	EUdraCT: 2005-003233-41	Summary Results
SEVELAMER CARBONATE	Renvela	Chronic Kidney Disease	SVCARB07609	NA	NCT01574326	Tabulated Results
SEVELAMER CARBONATE	Renvela	Chronic Kidney Disease	SVCARB10012	TOSCANA	NCT02332811	Summary
SEVELAMER CARBONATE	Renvela	Chronic Kidney Disease	APB00108	LEAP	NCT00853242	Tabulated Results
SEVELAMER CARBONATE	Renvela	Hyperphosphatemia	EFC14011	RECOVER	NCT03001011	Tabulated Results
SEVELAMER HYDROCHLORIDE	Renagel	Healthy Volunteers	GTC-02-101*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-10-201*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-10-202*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Healthy Volunteers	GTC-10-801*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-36-203*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-36-301*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-36-302*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-45-204*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-45-206*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Healthy Volunteers	GTC-45-803*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Healthy Volunteers	GTC-45-804*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Healthy Volunteers	GTC-45-807*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Healthy Volunteers	GTC-45-808*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-45-901*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-49-301*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-68-208*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	GTC-68-209	NA	NCT00324376	Publication's reference
SEVELAMER HYDROCHLORIDE	Renagel	Healthy Volunteers	ICR013769*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Healthy Volunteers	ICR013821*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	REN-001-00*	NA		Summary
SEVELAMER HYDROCHLORIDE	Renagel	Chronic Kidney Disease	REN-002-01*	NA		Summary
SODIUM HYALURONATE	Hyalgan	Arthritis	L_8229	HUPS	NCT00377624	Summary
SODIUM HYALURONATE	Hyalgan	Arthritis	L_9385	TREAD-20	NCT00130468	Summary
SODIUM HYALURONATE	Hyalgan	Arthritis	L_9385EXT	TREAD-20	NCT00830830	Summary
SOMATROPIN	Maxomat	Fetal Growth Retardation	FH5126A	NA	NCT00452491	Summary
SOMATROPIN	Maxomat	Growth Hormone Deficiency	L_8912	NA	NCT00476385	Summary
SOMATROPIN	Maxomat	Growth Hormone Deficiency	MAX08	NOONAN'S	NCT00452725	Summary
STABLE GLUCAGON	Not marketed	Diabetes Mellitus, Type 1	TDU14518	NA	NCT02625636	Summary
SUTIMLIMAB	ENJAYMO	Chronic Immune Thrombocytopenia	LTS16214	NA	NCT02502903	Publication Reference
SUTIMLIMAB	ENJAYMO	Cold Agglutinin Disease	EFC16215	Cardinal Study	NCT03347396	Tabulated Results

References:
*These study results were previously posted on GenzymeClinicalResearch.com
**This link replaces the same summary that was previously posted